or if already diagnosed, can slow progression to cirrhosis.(3) Current Guidelines: GLP-1 RA Use in Cirrhosis The guidelines for MASLD management, updated in 2024, are a collaborative effort between the European Association for the Study of the Liver, European Association for the Study of Diabetes, and European Association for the Study of Obesity
Under medical supervision, this dual mechanism may help: Side effects are usually mild, occur early in treatment, and reduce as the dose is titrated gradually
Telehealth is well-suited for GLP-1 management because the treatment requires frequent monitoring, especially during the dose escalation period
In ELIXA, the beneficial role of lixisenatide on UACR progression was evident only following statistical adjustments for predisposing factors in patients with baseline MA [12]
When used in combination, these medications work through complementary mechanisms to improve blood glucose control
A 2024 systematic review of 10 randomised controlled trials confirmed that the combination significantly improved HbA1c, fasting blood glucose, and BMI compared to metformin alone, with no increase in adverse events
